Phase 3 IFx-Hu2.0 trial as an adjunctive therapy with Keytruda ® (pembrolizumab) in checkpoint inhibitor (CPI)-naïve patients with advanced or metastatic Merkel cell carcinoma (MCC) detailed in Trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results